Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iva Lukac

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Medicinal Chemistry|October 29, 2021
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral LeishmaniasisCharles E Mowbray, Stéphanie Braillard, Paul A Glossop, et al.
Journal of Medicinal Chemistry|April 27, 2021
Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral LeishmaniasisMichael Thomas, Stephen Brand, Manu De Rycker, et al.
Journal of Medicinal Chemistry|November 10, 2023
Identification and Optimization of Novel Inhibitors of the Polyketide Synthase 13 Thioesterase Domain with Antitubercular ActivitySimon R Green, Caroline Wilson, Thomas C Eadsforth, et al.
Science Translational Medicine|October 23, 2024
<i>Cryptosporidium</i> lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacyNicola Caldwell, Caroline Peet, Peter Miller, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Medicinal Chemistry|October 29, 2021
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral LeishmaniasisCharles E Mowbray, Stéphanie Braillard, Paul A Glossop, et al.
Journal of Medicinal Chemistry|April 27, 2021
Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral LeishmaniasisMichael Thomas, Stephen Brand, Manu De Rycker, et al.
Journal of Medicinal Chemistry|November 10, 2023
Identification and Optimization of Novel Inhibitors of the Polyketide Synthase 13 Thioesterase Domain with Antitubercular ActivitySimon R Green, Caroline Wilson, Thomas C Eadsforth, et al.
Science Translational Medicine|October 23, 2024
<i>Cryptosporidium</i> lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacyNicola Caldwell, Caroline Peet, Peter Miller, et al.
Pageof 2